Our Research
Glaucoma Australia is committed to supporting research which focuses on the following research domains:
-
Increasing the rate and reliability of early detection of glaucoma
-
Developing new treatments or improving the treatment experience
-
Improving the quality and experience of monitoring the condition progression and maintaining better population wide statistics
-
Providing prevention or management tools to improve the quality of life for people with glaucoma.
We are excited to facilitate the innovative research of academics who drive progress in glaucoma management. Our broad aims are to improve the lives of people with glaucoma through better glaucoma detection and treatment.
Year | Recipient | Study / Grant |
---|---|---|
2023 | Prof David Mackey AO | What is the normal range if intraocular pressure in children and young adults, and does it predict later glaucoma? |
2022 | A/Prof Owen Siggs | Genomic Risk Stratification to Improve Glaucoma Suspect Triage in Rural Primary Care |
2021 | Professor Ewa Goldys University of New South Wales |
The fluorescent Hyperspectral Imaging (fHSI) technology, a novel imaging tool for the early detection and monitoring of glaucoma. |
2019 | Dr Flora Hui Centre for Eye Research Australia (CERA) |
TAMING Glaucoma Trial (Targeting Metabolic Insufficiency in Glaucoma with Nicotinamide) |
2019 | Dr George Kong Royal Victorian Eye and Ear Hospital |
Clinical trial to examine the validity of home monitoring using the world’s first software app for tablet devices for glaucoma patients. |
2019 | Prof Jamie Craig Flinders University |
Population level screening aims to provide evidence which drives early intervention to the highest risk individuals before vision loss occurs. |
2018 | Flinders University | TARRGET |
2017 | Flinders University | TARRGET |
2016 | Flinders University | TARRGET |
2016 | Dr Kathryn Burdon Ms Emmanuelle Souzeau |
Identifying genetic causes of primary congenital glaucoma in Australia |
2016 | Prof Jonathan Crowston Dr Ian Trounce |
Oxidative Phosphorylation defects and the optic nerve response to acute IOP injury in the xenomitochondrial mouse |
2015 | Westmead Hospital | |
2015 | A/Prof Robert Casson | Bioenergetic-Based Neuroprotection for the Treatment of Retinal and Optic |
2014 | Prof Jamie Craig Dr Alex Hewitt |
Proteomic and Genomic Strategies to Identify the Molecular Basis of PEX |
2013 | Prof Glen Gole Dr Nigel Barnett Prof Steven Bottle |
Evaluating a novel (two-way, ie reversible) technique to measure oxidation (or reduction) in retinal cells in an experimental glaucoma model |
2013 | Dr Alex Hewitt Dr Mirella Dottori Dr Bryony Nayagam |
Developing a patient-specific model for glaucoma |
2012 | Dr Glyn Chidlow | Investigations into optic nerve injury in a rat model of glaucoma |
2012 | Dr Kathryn Burdon Prof Jamie Craig Dr James Muecke Dr Adam Rudkin Dr Jillian Nicholl |
Genetic causes of childhood blindness in Sri Lanka and Cambodia |
2011 | A/Prof Robert Casson | Can Glucose Eye Drops Improve Vision in Glaucoma |
2011 | Dr Kathryn Burdon | Genetic Investigations of Central Corneal Thickness in Relation to Blinding Glaucoma |
2010 | Ms F O’Hare | Characteristics of auditory function in individuals with glaucoma |
2010 | Prof Jonathan Crowston Dr Paul Healey |
Regulating wound healing after glaucoma filtration surgery by priming Tenon’s fibroblast for apoptosis. |
2010 | Dr A. Martins Prof Stuart Graham Dr Alexander Klistorner |
Spectral (Blue-Yellow) Objective Perimetry in Normal and Diseased States |
2009 | Dr John Wood Dr Glyn Chidlow |
The Role of Tau in Experimental Glaucoma |
2009 | Prof David Mackey | The Twin Eye Studies in Tasmania to investigate genetic and environmental contributions to glaucoma and other eye diseases |
2009 | Dr Colin I Clement | Hyperhomocystinaemia in Glaucoma |
2008 | Dr Glyn Chidlow A/Prof Robert Casson |
The Role of Osteopontin in the Retina |
2008 | A/Prof Robert Casson | Bioenergetic-Based Neuroprotection for the Treatment of Retinal and Optic |
2007 | Dr Simon Skalicky | Glaucoma and Depression |
2007 | Prof Peter McCluskey Alex Dempster Prof ACB (Tony) Molteno Prof Denis Wakefield |
The Role of Matrix Metallooproteinases in the Development of Filtration Blebs following Molteno Valve Insertion |
2006 | Prof Minas T Coroneo Dr Agar Ashish Dr Mark Hill |
The Effects of Pressure on Retinal Ganglion Cell Survival In-Vitro |
2005 | Mr Michael Ward A/Prof Ross McKinnon |
Genetic determinants of beta-blocker eye drop efficacy in glaucoma patient |
2004 | Prof Jamie Craig Dr Nick Voelcker |
Miniaturised Implantable Sensors for Eye Pressure Measurement |
The Targeting At Risk Relatives of Glaucoma patients for Early diagnosis and Treatment (TARRGET) study is a partnership project between Glaucoma Australia, the Australian and New Zealand Registry of Advanced Glaucoma (ANZRAG, based at Flinders University, Adelaide) and the Lions Eye Institute (University of Western Australia).
The TArgeting Metabolic INsufficiency in Glaucoma with nicotinamide (TAMING) trial is a world-first randomised-controlled clinical trial to be conducted in partnership with Glaucoma Australia and the Centre for Eye Research Australia.
Glaucoma is the leading cause of irreversible blindness worldwide. For patients with glaucoma, the ability to detect any changes in their peripheral vision (visual field) is critical to their management. However the current practice of visual field testing in clinic is often not frequent enough, and some patient’s vision can deteriorate before their next routine clinic visit.
We can help your patients understand why appointment and treatment adherence is so important. Use our quick online form to refer now.
Order your free glaucoma patient resources and collateral for your practice. Digital downloads are also available.
Grow your practice when you list with Find a Health Professional or upgrade to online bookings. Your fee goes towards our continuous sight saving work.
Check out relevant and valuable opportunities for CME / CPD credits through Glaucoma Australia’s activities with partners.
Glaucoma Australia awards scholarships each year to enable trainees in glaucoma to attend the annual ANZGS Scientific Meeting.
Explore the globally distributed CME journal, recognised by RANZCO as valid CPD activity. Worldwide Glaucoma experts contribute.
We can help your patients understand why appointment and treatment adherence is so important. Refer your patients to us today and together we can save sight.
We have a range of free resources and tools to help your patient learn more about glaucoma.
Download and share our digital campaigns to help raise glaucoma awareness.